PETALING JAYA: Duopharma Biotech Bhd
aims to deliver a satisfactory performance in 2025, barring unforeseen market changes and developments.
In a filing with Bursa Malaysia, Duopharma said this would be achievable with a resolute focus on sustainable growth, cost optimisation and operational resilience.
For the fourth quarter ended Dec 31, 2024, Duopharma’s net profit rose to RM15.08mil from RM8.5mil in the previous corresponding period, while revenue grew to RM193.67mil from RM167.50mil a year earlier.
For the financial year ended Dec 31, 2024, Duopharma’s net profit rose to RM62.65mil from RM52.65mil a year earlier, while revenue improved to RM813.70mil from RM704.73mil previously.
Duopharma said the higher revenue was driven by robust sales across the public health, ethical specialty, and export segments, which offset the weaker-than-expected performance of the consumer healthcare sector.
“During the year, the group faced heightened operational costs, primarily driven by the full-scale operation of the newly completed K3 facility, increased finance costs and the impact of higher electricity tariffs and the amendments to the Employment Act 1955 introduced last year.
“Nevertheless, despite these challenges, the group’s robust revenue growth, coupled with the initial crystallisation of favourable impacts from industry-wide normalisation of Active Pharmaceutical Ingredient prices to pre-pandemic level, have cushioned these cost pressures.
